

**Ref. No.: NLL/CS/2025- 607**

**November 14, 2025**

To,  
National Stock Exchange of India Limited  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai 400 051  
**Symbol: NECLIFE**

BSE Limited  
Corporate Relationship Department,  
P J Towers, Dalal Street,  
Mumbai 400 001  
**Scrip Code: 532649**

**Sub: Outcome of Board Meeting**

**Ref.: Regulation 30 and 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulation").**

Dear Sir/ Madam,

We wish to inform you that the board of directors of Nectar Lifesciences Limited ("Company") in their meeting held on November 14, 2025, have, inter-alia, noted, decided and approved the unaudited standalone and consolidated financial results for the quarter and half year ended on September 30, 2025, which are enclosed herewith along with the limited review reports of the auditors thereon.

The Board Meeting commenced at 03:00 P.M. IST and concluded at 04:30 P.M. IST.

Kindly take the same on record.

Thanking you,

Yours faithfully,  
For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)  
**Company Secretary & Compliance Officer**



**Independent Auditor's review report on the Quarterly and Year to date Unaudited Standalone Financial Results of the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors of,  
Nectar Lifesciences Limited,  
Village Saidpura, Tehsil Derabassi,  
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Nectar Lifesciences Limited ("the Company") for the quarter and half year ended Sept 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review



is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deepak Jindal & Co.

Chartered Accountants

Firm Regn. No. 023023N



(Kashav Kaushal)

Partner

M. No. 517148

UDIN: 25517148 13M10ZL2773

Date: 14<sup>th</sup> Nov 2025

Place: Chandigarh



**Independent Auditors' review report on the Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended**

To

The Board of Directors

Nectar Lifesciences Limited

Village Saidpura, Tehsil Derabassi,

Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Nectar Lifesciences Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and six months ended Sep 30, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related consolidated financial statements and been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial & accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.




We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the subsidiaries listed as below: -
  - a. NECLIFE PT, UNIPESSOAL LDA (Inoperative)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the matter in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial results include the unaudited interim financial information of the subsidiary which have not been reviewed by their auditors, whose interim financial information excluding consolidation eliminations reflects total revenue of **Nil**, total net profit/ (loss) after tax of **Nil**, total comprehensive income of **Nil** for the quarter ended Sep 30, 2025 and six months ended Sep 30, 2025, respectively, as considered in the Statement. The unaudited financial information has been approved and furnished to us by the management. Our conclusion in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited financial information. According to the information and explanations given to us by management, this interim financial information's are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the management.

For Deepak Jindal & Co.  
Chartered Accountants  
Firm Regn. No. 023023N



Date: 14<sup>th</sup> Nov 2025  
Place: Chandigarh

M. No. 517148  
UDIN: 25517148BM102M7013


## Statement of Standalone Financial Results for the Quarter and half year ended 30.09.2025 (Rs in Lacs)

S. No.	Particulars	Quarter Ended			Half Year		Year Ended
		30-Sep-25	30-Jun-25 (Restated)	30-Sep-24 (Restated)	30-Sep-25 (Restated)	30-Sep-24 (Restated)	31-Mar-25 (Restated)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	<b>Income from Operations</b>						
	Sales	586.89	615.48	671.46	1,202.37	1,222.89	2,498.84
	Less: GST Recovered	87.23	92.12	98.82	179.35	179.50	366.88
	<b>Revenue from Operations</b>	<b>499.66</b>	<b>523.36</b>	<b>572.64</b>	<b>1,023.02</b>	<b>1,043.39</b>	<b>2,131.96</b>
	Other operating Income	71.45	0.63	0.62	72.08	1.25	2.50
II	Other Income	2.62	31.99	68.94	34.61	121.91	161.91
iii	<b>Total Income (I + II)</b>	<b>573.73</b>	<b>555.98</b>	<b>642.20</b>	<b>1,129.71</b>	<b>1,166.55</b>	<b>2,296.37</b>
IV	<b>Expenses</b>						
	(a) Cost of Materials consumed	341.04	336.58	375.04	677.62	748.32	1,512.09
	(b) Purchase of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5.59)	13.61	17.04	8.02	(20.55)	(43.35)
	(d) Employee benefits expense	75.17	70.27	68.30	145.44	136.14	273.20
	(e) Finance costs	-	0.02	0.06	0.02	0.07	0.74
	(f) Depreciation and amortisation expense	20.41	52.53	45.00	72.94	96.95	208.04
	(g) Other expenses	193.32	187.57	171.80	380.89	336.06	641.46
	<b>Total Expenses (IV)</b>	<b>624.35</b>	<b>660.58</b>	<b>677.24</b>	<b>1,284.93</b>	<b>1,296.99</b>	<b>2,592.18</b>
V	<b>Profit before exceptional items and tax (III- IV)</b>	<b>(50.62)</b>	<b>(104.60)</b>	<b>(35.04)</b>	<b>(155.22)</b>	<b>(130.44)</b>	<b>(295.81)</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Profit from ordinary activities before tax (V - VI)</b>	<b>(50.62)</b>	<b>(104.60)</b>	<b>(35.04)</b>	<b>(155.22)</b>	<b>(130.44)</b>	<b>(295.81)</b>
VIII	<b>Tax Expense</b>						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	(17.69)	(36.55)	(12.24)	(54.24)	(45.58)	(103.37)
IX	<b>Profit for the period from continuing operations (VII-VIII)</b>	<b>(32.93)</b>	<b>(68.05)</b>	<b>(22.80)</b>	<b>(100.98)</b>	<b>(84.86)</b>	<b>(192.44)</b>
	Profit before tax for the period from discontinued operations (Refer Note 6)	(27,001.61)	(9,570.83)	901.65	(36,572.44)	1,488.76	(15,857.59)
	Tax expenses of discontinued operations	(9,433.97)	(3,315.80)	318.96	(12,749.77)	547.10	(4,681.96)
	<b>Profit for the period from discontinued operations</b>	<b>(17,567.64)</b>	<b>(6,255.03)</b>	<b>582.69</b>	<b>(23,822.67)</b>	<b>941.66</b>	<b>(11,175.63)</b>
	<b>Total Profit for the period</b>	<b>(17,600.57)</b>	<b>(6,323.08)</b>	<b>559.89</b>	<b>(23,923.65)</b>	<b>856.80</b>	<b>(11,368.07)</b>
	<b>Other Comprehensive Income</b>						
	<b>Items that will not be reclassified subsequently to profit or loss</b>						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	53.98
	<b>Items that will be reclassified subsequently to profit or loss</b>						
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	-	-
	<b>Total Other Comprehensive Income, (Net of Tax)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>53.98</b>
	<b>Total Comprehensive Income for the period</b>	<b>(17,600.57)</b>	<b>(6,323.08)</b>	<b>559.89</b>	<b>(23,923.65)</b>	<b>856.80</b>	<b>(11,314.09)</b>
X	<b>Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up) (before and after exceptional item)</b>						
	a) Basic continuing operations (In Rs.)	(0.01)	(0.03)	(0.01)	(0.05)	(0.04)	(0.09)
	b) Diluted continuing operations (In Rs.)	(0.01)	(0.03)	(0.01)	(0.05)	(0.04)	(0.09)
	c) Basic discontinued operations (In Rs.)	(7.83)	(2.79)	0.26	(10.62)	0.42	(4.98)
	d) Diluted discontinued operations (In Rs.)	(7.83)	(2.79)	0.26	(10.62)	0.42	(4.98)
	e) Basic continuing & discontinued operations (In Rs.)	(7.85)	(2.82)	0.25	(10.67)	0.38	(5.07)




Statement of Consolidated Financial Results for the Quarter and half year ended 30.09.2025 (Rs in Lacs)

S. No.	Particulars	Quarter Ended			Half Year		Year Ended
		30-Sep-25	30-Jun-25 (Restated)	30-Sep-24 (Restated)	30-Sep-25 (Restated)	30-Sep-24 (Restated)	31-Mar-25 (Restated)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	<b>Income from Operations</b>						
	Sales	586.89	615.48	671.46	1,202.37	1,222.89	2,498.84
	Less: GST Recovered	87.23	92.12	98.82	179.35	179.50	366.88
	<b>Revenue from Operations</b>	<b>499.66</b>	<b>523.36</b>	<b>572.64</b>	<b>1,023.02</b>	<b>1,043.39</b>	<b>2,131.96</b>
	Other operating Income	71.45	0.63	0.62	72.08	1.25	2.50
II	Other Income	2.62	31.99	68.94	34.61	121.91	161.91
III	<b>Total Income (I + II)</b>	<b>573.73</b>	<b>555.98</b>	<b>642.20</b>	<b>1,129.71</b>	<b>1,166.55</b>	<b>2,296.37</b>
IV	<b>Expenses</b>						
	(a) Cost of Materials consumed	341.04	336.58	375.04	677.62	748.32	1,512.09
	(b) Purchase of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5.59)	13.61	17.04	8.02	(20.55)	(43.35)
	(d) Employee benefits expense	75.17	70.27	68.30	145.44	136.14	273.20
	(e) Finance costs	-	0.02	0.06	0.02	0.07	0.74
	(f) Depreciation and amortisation expense	20.41	52.53	45.00	72.94	96.95	208.04
	(g) Other expenses	193.32	187.57	171.80	380.89	336.06	641.46
	<b>Total Expenses (IV)</b>	<b>624.35</b>	<b>660.58</b>	<b>677.24</b>	<b>1,284.93</b>	<b>1,296.99</b>	<b>2,592.18</b>
V	<b>Profit before exceptional items and tax (III- IV)</b>	<b>(50.62)</b>	<b>(104.60)</b>	<b>(35.04)</b>	<b>(155.22)</b>	<b>(130.44)</b>	<b>(295.81)</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Profit from ordinary activities before tax (V - VI)</b>	<b>(50.62)</b>	<b>(104.60)</b>	<b>(35.04)</b>	<b>(155.22)</b>	<b>(130.44)</b>	<b>(295.81)</b>
VIII	<b>Tax Expense</b>						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	(17.69)	(36.55)	(12.24)	(54.24)	(45.58)	(103.37)
IX	<b>Profit for the period from continuing operations (VII-VIII)</b>	<b>(32.93)</b>	<b>(68.05)</b>	<b>(22.80)</b>	<b>(100.98)</b>	<b>(84.86)</b>	<b>(192.44)</b>
	Profit before tax for the period from discontinued operations (Refer Note 6)	(27,001.61)	(9,570.83)	901.65	(36,572.44)	1,488.76	(15,857.59)
	Tax expenses of discontinued operations	(9,433.97)	(3,315.80)	318.96	(12,749.77)	547.10	(4,681.96)
	<b>Profit for the period from discontinued operations</b>	<b>(17,567.64)</b>	<b>(6,255.03)</b>	<b>582.69</b>	<b>(23,822.67)</b>	<b>941.66</b>	<b>(11,175.63)</b>
	<b>Total Profit for the period</b>	<b>(17,600.57)</b>	<b>(6,323.08)</b>	<b>559.89</b>	<b>(23,923.65)</b>	<b>856.80</b>	<b>(11,368.07)</b>
	<b>Other Comprehensive Income</b>						
	<b>Items that will not be reclassified subsequently to profit or loss</b>						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	53.98
	<b>Items that will be reclassified subsequently to profit or loss</b>						
	Foreign Exchange Translation Reserve (Net of Tax)	-	0.01	-	0.01	-	-
	<b>Total Other Comprehensive Income, (Net of Tax)</b>	<b>-</b>	<b>0.01</b>	<b>-</b>	<b>0.01</b>	<b>-</b>	<b>53.98</b>
	<b>Total Comprehensive Income for the period</b>	<b>(17,600.57)</b>	<b>(6,323.07)</b>	<b>559.89</b>	<b>(23,923.64)</b>	<b>856.80</b>	<b>(11,314.09)</b>
X	<b>Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up) (before and after exceptional item)</b>						
	a) Basic continuing operations (In Rs.)	(0.01)	(0.03)	(0.01)	(0.05)	(0.04)	(0.09)
	b) Diluted continuing operations (In Rs.)	(0.01)	(0.03)	(0.01)	(0.05)	(0.04)	(0.09)
	c) Basic discontinued operations (In Rs.)	(7.83)	(2.79)	0.26	(10.62)	0.42	(4.98)
	d) Diluted discontinued operations (In Rs.)	(7.83)	(2.79)	0.26	(10.62)	0.42	(4.98)
	e) Basic continuing & discontinued operations (In Rs.)	(7.85)	(2.82)	0.25	(10.67)	0.38	(5.07)
	f) Diluted continuing & discontinued operations (In Rs.)	(7.85)	(2.82)	0.25	(10.67)	0.38	(5.07)



## Notes

- 1 The above financial results were reviewed by Audit Committee on November 14, 2025 and approved by the Board of Nectar Lifesciences Limited ('Company') in its meeting held on November 14, 2025. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone and consolidated unaudited financial results/ statements for the quarter and half year ended on September 30, 2025.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 4 The Statement of Assets and Liability is attached as Annexure 1.
- 5 The Statement of Cash Flow is attached as Annexure 2.
- 6 The Company has undertaken following transactions during the quarter:
  - i. On July 7, 2025, the Company entered into a Business Transfer Agreement ('BTA') for transfer of its Active Pharmaceutical Ingredients (located at Unit 1 And Unit 2 at Derabassi, Punjab and at Unit 6, Baddi, Himachal Pradesh) ('Pharma Business') to Ceph Lifesciences Private Limited by way of a slump sale, on going concern basis for a total consideration of ₹ 127,000 lacs.
  - ii. In addition, the company also entered into an agreement to transfer assets of the Company in relation to its menthol business ("Assets" vide Asset Purchase Agreement (APA) dated July 7, 2025 to Ceph Lifesciences Private Limited for a consideration of ₹2,000 lacs.
  - iii. The Company had expected to realise a consolidated amount of INR 129,000 lacs from the above transfers, subject to working capital adjustments. This proposed transfer of Pharma Business and Assets has been approved by the Shareholders of the Company by way of special resolution on August 04, 2025. The slump sale and Assets sale has been completed on November 10 2025 and accordingly after such working capital adjustments as per BTA, the final consolidated consideration has been worked out as ₹ 127,398.55 lacs including ₹ 2,000 lacs of Assets sale.
  - iv. Consequently, In the Standalone Financial Statements, Assets and liabilities of "Pharma business" and "Assets" covered by the BTA and APA have been disclosed as held for sale and disclosed separately in the Balance Sheet as at September 30, 2025 as "Assets of discontinued operations classified as held for sale" and "Liabilities of discontinued operations classified as held for sale" respectively. As mandated by Indian Accounting Standard (Ind AS) 105 Asset Held for Sale and Discontinued Operations ("Ind AS 105"), assets and liabilities have not been reclassified or re-presented for prior period i.e. year ended March 31, 2025.
  - v Further the net results of "Pharma Business" and "Assets" have been disclosed separately as discontinued operation as required by Ind AS 105. Consequently, the Company's Statement of Profit and Loss for the period ended September 30, 2025 presented pertains to its continuing operations only and for that purpose the Statement of Profit and Loss for the quarter ended June 30, 2025, September 30, 2024 has been restated accordingly.



vi The closing date being subsequent to the balance sheet date, no gain/loss with respect to the Divestment have been recognized in the Statement of Profit and Loss for the quarter ended September 30, 2025. The total assets and liabilities of the Pharma business and Assets are Rs 133520.87 lacs and Rs 37186.42 lacs respectively as at September 30, 2025.

vii Operations relating to the "Pharma Business" and "Assets" in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below:

S. No.	Particulars	Quarter Ended			Half year		Year Ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	8,827.36	27,543.15	42,215.82	36,370.51	77,629.77	1,64,865.40
2	Other income	2.56	3.00	20.71	5.56	67.46	334.75
3	Total expenses	35,831.53	37,116.98	41,334.88	72,948.51	76,208.47	1,81,057.74
4	<b>Profit before tax</b>	<b>(27,001.61)</b>	<b>(9,570.83)</b>	<b>901.65</b>	<b>(36,572.44)</b>	<b>1,488.76</b>	<b>(15,857.59)</b>
5	Tax expenses	(9,433.97)	(3,315.80)	318.96	(12,749.77)	547.10	(4,681.96)
6	<b>Net profit after tax</b>	<b>(17,567.64)</b>	<b>(6,255.03)</b>	<b>582.69</b>	<b>(23,822.67)</b>	<b>941.66</b>	<b>(11,175.63)</b>

Dated: 14.11.2025

Place: Chandigarh



By Order of the Board of Directors  
of Nectar Lifesciences Limited

(Sanjiv Goyal)  
Chairman & Managing Director





## Annexure 1

## Statement of Assets and Liabilities

(Rs. in Lakhs)

Sr.	Particulars	Standalone				Consolidated			
		As at		As at		As at		As at	
		30-Sep-25	31-Mar-25	30-Sep-25	31-Mar-25	30-Sep-25	31-Mar-25	30-Sep-25	31-Mar-25
		Unaudited	(Restated)	Unaudited	(Restated)	Unaudited	(Restated)	Unaudited	(Restated)
	<b>Assets</b>								
<b>1</b>	<b>Non-current assets</b>								
	Property, plant and equipment	2,759.11	57,660.46	2,759.11	57,660.46				
	Capital work-in-progress	-	5,672.83	-	5,672.83				
	Investment property	-	-	-	-				
	Goodwill	-	-	-	-				
	Other intangible assets	-	5,650.43	-	5,650.43				
	Intangible assets under development	-	-	-	-				
	Biological assets other than bearer plants	-	-	-	-				
	Inventories	-	5,061.27	-	5,061.27				
	Investments accounted for using equity method	-	-	-	-				
	Non-current investments	24.31	24.31	23.51	23.51				
	Trade receivables, non-current	697.30	848.71	697.30	848.71				
	Loans, non-current	-	-	-	-				
	Other non-current financial assets	50.42	325.12	50.42	325.12				
	Deferred tax assets (net)	18,308.16	5,504.15	18,308.11	5,504.10				
	Other non-current assets	217.35	217.35	217.35	217.35				
	<b>Total non-current assets</b>	<b>22,056.65</b>	<b>80,964.63</b>	<b>22,055.80</b>	<b>80,963.78</b>				
<b>2</b>	<b>Current assets</b>								
	Inventories	298.32	69,015.96	298.32	69,015.96				
	Current investments	52.95	52.95	52.95	52.95				
	Trade receivables, current	5,429.60	34,548.47	5,429.60	34,548.47				
	Cash and cash equivalents	592.84	1,921.97	593.02	1,922.16				
	Bank balance other than cash and cash equivalents	-	-	-	-				
	Loans, current	87.48	85.69	87.48	85.69				
	Other current financial assets	751.22	751.22	751.22	751.22				
	Current tax assets (net)	-	-	-	-				
	Other current assets	18,686.55	17,382.24	18,686.55	17,382.24				
	<b>Total current assets</b>	<b>25,898.96</b>	<b>1,23,758.50</b>	<b>25,899.14</b>	<b>1,23,758.69</b>				
<b>3</b>	<b>Non-current assets classified as held for sale</b>	<b>1,33,520.87</b>	<b>-</b>	<b>1,33,520.87</b>	<b>-</b>				
<b>4</b>	<b>Regulatory deferral account debit balances and related deferred tax Assets</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>				
	<b>Total assets</b>	<b>1,81,476.48</b>	<b>2,04,723.13</b>	<b>1,81,475.81</b>	<b>2,04,722.47</b>				
	<b>Equity and liabilities</b>								
<b>1</b>	<b>Equity</b>								
	<b>Equity attributable to owners of parent</b>								
	Equity share capital	2,242.61	2,242.61	2,242.61	2,242.61				
	Other equity	69,445.10	93,368.73	69,444.43	93,368.07				
	<b>Total equity attributable to owners of parent</b>	<b>71,687.71</b>	<b>95,611.34</b>	<b>71,687.04</b>	<b>95,610.68</b>				
	Non controlling interest	-	-	-	-				
	<b>Total equity</b>	<b>71,687.71</b>	<b>95,611.34</b>	<b>71,687.04</b>	<b>95,610.68</b>				
<b>2</b>	<b>Liabilities</b>								
	<b>Non-current liabilities</b>								
	<b>Non-current financial liabilities</b>								
	Borrowings, non-current	1,331.43	6,012.73	1,331.43	6,012.73				
	Lease liabilities	-	-	-	-				
	Trade payables, non-current	-	-	-	-				
	(A) total outstanding dues of micro enterprises and small enterprises;	-	-	-	-				
	(B) total outstanding dues of creditors other than micro enterprises and small enterprises	-	-	-	-				
	Other non-current financial liabilities	-	-	-	-				
	Provisions, non-current	-	872.84	-	872.84				
	Deferred tax liabilities (net)	-	-	-	-				
	Deferred government grants, Non-current	-	-	-	-				
	Other non-current liabilities	-	72.08	-	72.08				
	<b>Total non-current liabilities</b>	<b>1,331.43</b>	<b>6,957.65</b>	<b>1,331.43</b>	<b>6,957.65</b>				
	<b>Current liabilities</b>								
	<b>Current financial liabilities</b>								
	Borrowings, current	44,553.42	52,189.54	44,553.42	52,189.54				
	Lease liabilities	-	-	-	-				
	Trade payables, current	-	-	-	-				
	(A) total outstanding dues of micro enterprises and small enterprises;	21.99	875.54	21.99	875.54				
	(B) total outstanding dues of creditors other than micro enterprises and small enterprises	210.50	42,936.08	210.50	42,936.08				
	Other current financial liabilities	26,232.78	4,977.27	26,232.78	4,977.27				
	Other current liabilities	231.11	883.50	231.11	883.50				
	Provisions, current	21.12	292.21	21.12	292.21				
	Current tax liabilities (Net)	-	-	-	-				
	Deferred government grants, Current	-	-	-	-				
	<b>Total current liabilities</b>	<b>71,270.92</b>	<b>1,02,154.14</b>	<b>71,270.92</b>	<b>1,02,154.14</b>				
	Liabilities directly associated with assets in disposal group classified as held for sale	37,186.42	-	37,186.42	-				
	Regulatory deferral account credit balances and related deferred tax liability	-	-	-	-				
	<b>Total liabilities</b>	<b>1,09,788.77</b>	<b>1,09,111.79</b>	<b>1,09,788.77</b>	<b>1,09,111.79</b>				
	<b>Tot equity and liabilities</b>	<b>1,81,476.48</b>	<b>2,04,723.13</b>	<b>1,81,475.81</b>	<b>2,04,722.47</b>				

Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current year figures.



**Unaudited Cash Flow Statement**

(Rs. in Lakhs)

PARTICULARS	Standalone		Consolidated	
	Half year ended		Half year ended	
	30-Sep-25	30-Sep-24 (Restated)	30-Sep-25	30-Sep-24 (Restated)
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>				
Profit before tax from continuing operations	(155.21)	(130.44)	(155.21)	(130.44)
Profit before tax from discontinued operations	(36,572.44)	1,488.76	(36,572.44)	1,488.76
Adjustments For :	-	-	-	-
Depreciation & Amortization	2,198.44	3,100.90	2,198.44	3,100.90
Other Comprehensive Income (Net)	-	-	-	-
Other Comprehensive Income (Tax)	-	-	-	-
Provision for Doubtful debts/ Insurance Claims	(126.72)	170.81	(126.72)	170.81
Provision for Employees Retirement Benefits	74.40	96.70	74.40	96.70
Provision for Excise Duty On Finished Goods	-	-	-	-
Loss/ (Profit) on Sale of Fixed Assets	32.06	-	32.06	-
Interest on Borrowings	3,454.77	3,978.47	3,454.77	3,978.47
Other Non-Operating Income	(37.62)	(124.02)	(37.62)	(124.02)
<b>OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES</b>	<b>(31,132.32)</b>	<b>8,581.18</b>	<b>(31,132.32)</b>	<b>8,581.18</b>
Adjustments For :	-	-	-	-
(Increase)/Decrease in Current Assets	29,144.90	(2,487.44)	29,144.90	(2,487.44)
Increase/(Decrease) in Current Liabilities	12,992.08	(1,092.50)	12,992.08	(1,092.50)
Increase/(Decrease) in Long Term Liabilities	-	-	-	-
Increase/ (Decrease) in Non Current Liabilities	(72.08)	(1.25)	(72.08)	(1.25)
(Increase)/ Decrease in Non Current Assets	4,335.90	(1.34)	4,335.90	(1.34)
<b>CASH GENERATED FROM OPERATIONS</b>	<b>15,268.48</b>	<b>4,998.65</b>	<b>15,268.48</b>	<b>4,998.65</b>
Direct Taxes Paid	-	-	-	-
<b>CASH FLOW BEFORE EXTRA-ORDINARY ITEMS</b>	<b>15,268.48</b>	<b>4,998.65</b>	<b>15,268.48</b>	<b>4,998.65</b>
Extra-Ordinary Items	-	-	-	-
<b>NET CASH FLOW FROM OPERATING ACTIVITIES (A)</b>	<b>15,268.48</b>	<b>4,998.65</b>	<b>15,268.48</b>	<b>4,998.65</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>				
Purchase of Fixed Assets	(893.13)	(658.75)	(893.13)	(658.75)
Sale of Fixed Assets	32.36	-	32.36	-
Interest Received	37.58	100.05	37.58	100.05
Dividend Received	0.04	-	0.04	-
Maturity of insurance policies	-	23.97	-	23.97
Other Financial Assets Received/ (Paid)	-	-	-	-
<b>NET CASH USED IN INVESTING ACTIVITIES (B)</b>	<b>(823.15)</b>	<b>(534.73)</b>	<b>(823.15)</b>	<b>(534.73)</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds/(Repayment) from Term Loans from Banks	(9,965.78)	(4,180.97)	(9,965.78)	(4,180.97)
Proceeds/(Repayment) from Working Capital Limits from Banks	(2,331.48)	3,552.81	(2,331.48)	3,552.81
Proceeds/(Repayment) from Vehicle Loans	(20.16)	(13.88)	(20.16)	(13.88)
Dividend Paid	-	-	-	-
Interest Paid	(3,454.77)	(3,978.47)	(3,454.77)	(3,978.47)
<b>NET CASH GENERATED FROM FINANCING ACTIVITIES (C)</b>	<b>(15,772.19)</b>	<b>(4,620.51)</b>	<b>(15,772.19)</b>	<b>(4,620.51)</b>
<b>NET INCREASE/(DECREASE) IN CASH &amp; CASH EQUIVALENTS (A+B+C)</b>	<b>(1,326.86)</b>	<b>(156.59)</b>	<b>(1,326.86)</b>	<b>(156.59)</b>
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	1,921.97	1,980.42	1,922.16	1,980.60
CASH & CASH EQUIVALENTS AT THE CLOSE OF THE YEAR	595.11	1,823.83	595.30	1,824.01

